- Conditions
- Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
- Interventions
- Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 25,236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 20,419 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 105
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose)
- Biological · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Melbourne, Florida
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV Vaccine, Non-exposure to RSV Vaccine
- Biological · Other
- Lead sponsor
- CorEvitas
- Network
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 2,062 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus
- Interventions
- mRNA-1345, mRNA-1365, Placebo, Nimenrix
- Biological · Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 5 Months to 24 Months
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
- Conditions
- RSV Infection
- Interventions
- Nirsevimab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 3,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Missoula, Montana • Norfolk, Nebraska
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 vaccine, Control
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 49 Years · Female only
- Enrollment
- 3,855 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
- Conditions
- Healthy
- Interventions
- RSV Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 10,212 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 770 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Waterbury, Connecticut • Brooksville, Florida • Immokalee, Florida + 6 more
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Interventions
- mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Riverside, California + 15 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3,317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV-F Particle Vaccine, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy
- Interventions
- IVX-A12, Placebo
- Biological
- Lead sponsor
- Icosavax, Inc.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- VRC-RSVRGP084-00-VP, Aluminum Hydroxide Suspension
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
- Biological · Other
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more
- Conditions
- RSV Immunization
- Interventions
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 2,226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
- Conditions
- RSV Infection
- Interventions
- Candidate vaccine, SCB-1019T, AREXVY, placebo
- Biological · Other
- Lead sponsor
- Clover Biopharmaceuticals USA, LLC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
- Conditions
- Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
- Interventions
- RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
- Biological · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 17
- States / cities
- Gadsden, Alabama • Scottsdale, Arizona • Long Beach, California + 14 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 23 Months
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
- Conditions
- RSV Infection
- Interventions
- RSVpreF, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 28 more